Johnson & Johnson MedTech Advances AI in Surgery

Key highlights
  • The Polyphonic AI Fund for Surgery was announced in June 2025.
  • The initiative involves companies like NVIDIA and AWS.
  • The first QuickFire Challenge awarded Mayo Clinic and QAS.AI.
  • The second round of the QuickFire Challenge opens in October.

Initiative Launch

In June 2025, Johnson & Johnson MedTech announced the Polyphonic AI Fund for Surgery to foster AI-driven innovations in surgical care. The initiative is supported by the Polyphonic Digital Ecosystem and involves collaboration with companies like NVIDIA and Amazon Web Services (AWS).

QuickFire Challenge

The Polyphonic AI Fund for Surgery QuickFire Challenge aims to accelerate AI solutions in surgery. The first round awarded Mayo Clinic and QAS.AI, providing them with funding, mentorship, and access to computing tools to advance their projects.

Focus Areas

Submissions for the QuickFire Challenge came from 29 countries, focusing on perioperative decision-making, surgical efficiency, and data management. Many projects explored multimodal AI to enhance surgical precision and decision-making, while others aimed to reduce variability in outcomes and improve interoperability.

Future Plans

The second round of the QuickFire Challenge opens in October, continuing support for the developer community. First-round applicants will join a network of innovators, gaining access to programming, mentorship, and networking opportunities to advance surgical AI solutions globally.

Source: J&J

chemXplore Weekly

The week’s project milestones and project news from the chemical industry, free every Wednesday.

Free. One email a week. Unsubscribe any time.

Related articles

19 June 2026
Johnson & Johnson: MEMBRANE shows MMA embolization with TRUFILL n‑BCA reduces cSDH recurrence

Randomized MEMBRANE trial found adding middle meningeal artery embolization with TRUFILL n‑BCA to standard care lowered chronic subdural hematoma recurrence and re‑intervention.

13 April 2026
Johnson & Johnson reports positive 12‑month VARIPULSE results at EHRA 2026

12‑month post‑market study: 84.2% freedom from atrial arrhythmia (90.5% paroxysmal; 75.3% persistent); 0.8% primary adverse events; CE‑mark allows ablation beyond pulmonary veins

19 December 2025
Johnson & Johnson Supports HRS Registry for PFA Data Collection

The registry will gather real-world data on PFA for AFib, aiming to improve treatment strategies and outcomes in electrophysiology.

18 December 2025
Johnson & Johnson's TRUFILL n-BCA Approved by FDA for Chronic Subdural Hematoma Treatment

FDA approves TRUFILL n-BCA for MMA embolization in chronic subdural hematoma, offering a minimally invasive alternative to surgery with proven safety and effectiveness.

3 November 2025
Johnson & Johnson Validates IVL Durability in Complex BTK Cases at VIVA 2025

DISRUPT BTK II study shows IVL's effectiveness in treating calcified lesions, reducing amputations, and improving quality of life for PAD patients.